Trial Profile

A Phase 3 Trial to Evaluate the Long-Term Safety and Efficacy of Navenibart in Participants With Hereditary Angioedema - ORBIT-EXPANSE

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 07 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Navenibart (Primary)
Indications Hereditary angioedema
Focus Adverse reactions; Registrational
Acronyms ORBIT-EXPANSE
Sponsors Astria Therapeutics; BioCryst Pharmaceuticals

Most Recent Events

04 May 2026 According to a BioCryst Pharmaceuticals media release, phase 3 program is on track to support regulatory filing by the end of 2027.
23 Jan 2026 According to a BioCryst Pharmaceuticals media release, Astria Therapeutics has been acquired and merged into BioCryst Pharmaceutical.
12 Nov 2025 According to an Astria Therapeutics media release, First Patient Now Enrolled in the ORBIT-EXPANSE Long-Term Extension trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com